FDA’s Generic Regulatory Science Plan Taking Broad-brush Approach So Far
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency lists five topics for industry and stakeholders to focus on during a June 21 meeting on what its fiscal year 2014 priorities should be; among issues for consideration are prioritizing projects based on public health impact and identifying challenges that limit the availability of generic drugs.